FDA Gives Greenlight to Inovio, GeneOne to Begin Zika Vaccine Study

The FDA has given the green light to Inovio Pharmaceuticals and GeneOne Life Science to commence a Phase 1 clinical trial to evaluate their Zika vaccine GLS-5700.

The 40-patient trial will evaluate the vaccine’s safety, tolerability and immunogenicity.

Inovio President and CEO Joseph Kim says the first subjects are scheduled to be dosed within the next weeks, and that the drugmakers expect to report Phase 1 interim results later this year.